Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 6575 | Ordered by Date (descending)
1 2 3 ... 64 65 66  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Ra Pharmaceuticals–UCB: investment, 201910– acquisition $2.5b in cash for $48/share incl acquired net cash of $315m ANNOUNCED 2019-10-10
Celmatix–Evotec: drug discovery services, 201910– collab €na developm pre-clinical programs for reproductive women’s health 2019-10-09
Novo Group–Bluebird Bio: gene therapy, 201910–202209 collab r+d 3y utilising megaTAL technology to develop hemophilia A gene therapies 2019-10-09
GSK–Lyell Immunopharma: cancer cell therapy, 201910–202409 collab 5y developm of technologies to improve cancer cell therapies 2019-10-08
Dalhousie Univ–Thermo Fisher: mass spectrometer, 201910 supply C$1.3m of Orbitrap Fusion MS system to MS + Proteomics Core Faclity 2019-10-07
Illumina–Qiagen: sequencing-based IVD tests, 201910–2034 collab 15y strategic alliance combining sequencing technology + assays + automation + s/w 2019-10-07
Korro Bio–New Enterprise Associates: investment, 201910 existing investor NEA 2019-10-07
Aeovian Pharmaceuticals–Apollo Ventures: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Apollo Health Ventures 2019-10-03
Aeovian Pharmaceuticals–Evotec: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Evotec 2019-10-03
Aeovian Pharmaceuticals–MacDougall Biomedical Communications: public relations, 201910 service existent by MacDougall 2019-10-03
Aeovian Pharmaceuticals–SEVERAL: investment, 201910 financing round Series A $37m led by VenBio + Sofinnova Investments 2019-10-03
Aeovian Pharmaceuticals–Sofinnova: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor Sofinnova Investments 2019-10-03
Aeovian Pharmaceuticals–VenBio: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor VenBio Partners 2019-10-03
Frequency Therapeutics–SEVERAL: investment, 201910 IPO $84m+$12.6m with 6m+900k shares common stock at $14/share at Nasdaq Global Select Market 2019-10-03
Immunexpress–SEVERAL: investment, 201910 private financing round 2019-10-03
Congenica–Genomenon: genomic software tools, 201910– collab integration of Mastermind Genomic Search Engine into clinical decision support s/w 2019-10-02
Elicio Therapeutics–SEVERAL: investment, 201910 financing round Series B $33m incl Clal + Livzon + Efung Capital 2019-10-02
Freiberg Instruments–Bruker Corp: investment, 201910 acquisition €na of Magnettech EPR business by Bruker 2019-10-02
Frequency Therapeutics–Kendall Investor Relations: public relations, 201910 supply service existent IR by Kendall IR 2019-10-02
Frequency Therapeutics–ScientPR: public relations, 201910 supply service existent media relations by Scient Public Relations Inc 2019-10-02
Geneoscopy–SEVERAL: investment, 201910 financing round Series A $6.9m led by Cultivation Capital + NT Investments + incl Lightchain Capital 2019-10-02
SEngine Precision Medicine–SEVERAL: investment, 201910 financing round Series A $5.1m led by Bangarang Group with family offices + existing investors 2019-10-02
Cellectis–Lonza: cell therapy contract manufacturing, 201910– supply UCART cell therapy candidates by Lonza in Geleen (NL) 2019-10-01
Novartis–Microsoft: artificial intelligence, 201910– collab strategic multiyear AI for drug r+d + commercialisation 2019-10-01
Creoptix–SEVERAL: investment, 201909 financing round Series 1st closing CHF8m incl investors Swisscanto Invest + Waters 2019-09-30
Creoptix–Waters: investment, 201909 financing round Series 1st closing totalling CHF8m incl existing + co-investor Waters Corp 2019-09-30
Creoptix–Zürcher Kantonalbank: investment, 201909 financing round Series 1st closing totalling CHF8m incl new + lead investor Swisscanto Invest 2019-09-30
Roper Technologies–AMETEK: investment, 201909– acquisition $925m in cash of Gatan Inc from Roper Technologies by AMETEK 2019-09-27
Addex–SEVERAL: investment, 201909– filing of Nadaq lisiting of ADSs (without proposing to register any new issuance of secutiries) 2019-09-24
Takeda–Evotec: drug discovery services, 201909– collab strategic multi-year across multiple indications 2019-09-24
AC Immune–LaVoieHealthScience: public relations, 201909– supply service existent US media relations by LHS 2019-09-20
AC Immune–LifeSci: public relations, 201909 supply service existent European investor + media relations by LifeSci Advisors 2019-09-20
Boehringer–Inflammasome: drug delivery technology, 201909– co-developm + license up to 3 retinal disease therapies using IVT drug delivery 2019-09-20
Bruker Corp–Murdoch Univ: analytical technologies, 201909– collab strategic alliance with ANPC incl MS + NMR for phenomics research 2019-09-20
Innate Pharma–SEVERAL: investment, 201909– filed US IPO + listing of ADSs at Nasdaq Global Market 2019-09-20
Murdoch Univ–Bruker Corp: NMR spectrometer, 201909 supply NMR FoodScreener 2019-09-20
Boundless Bio–Alexandria Real Estate: investment, 201909 financing round Series A totalling $46m incl co-investor Alexandria Venture Investments 2019-09-19
Boundless Bio–ARCH Venture: investment, 201909 financing round Series A totalling $46m incl co-lead investor ARCH Venture Partners 2019-09-19
Boundless Bio–City Hill Ventures: investment, 201909 financing round Series A totalling $46m incl co-lead investor City Hill Ventures 2019-09-19
Boundless Bio–GT Healthcare Capital Partners: investment, 201909 financing round Series A totalling $46m incl co-investor GT Healthcare CP 2019-09-19
Boundless Bio–SEVERAL: investment, 201909 financing round Series A $46m co-led by ARCH Venture Partners + City Hill Ventures 2019-09-19
Boundless Bio–Tavistock: investment, 201909 financing round Series A totalling $46m incl co-investor Boxer Capital 2019-09-19
Boundless Bio–Temasek: investment, 201909 financing round Series A totalling $46m incl co-investor Vertex Ventures 2019-09-19
Boundless Bio–WPP: public relations, 201909 service existent by Glover Park Group 2019-09-19
China (govt)–Agilent: grant, 201909– Thought Leader Award to Hualiang Jiang at SIMM CAS for work in medicinal chemistry + drug discovery 2019-09-19
Ginkgo Bioworks–Bateman Group: public relations, 201909 service existent by Bateman Group 2019-09-19
Ginkgo Bioworks–SEVERAL: investment, 201909 financing round Series E $290m incl funds + accounts advised by T Rowe Price Associates 2019-09-19
Ginkgo Bioworks–T Rowe Price Associates: investment, 201909 financing round Series E totalling $290m incl funds + accounts advised by T Rowe Price 2019-09-19
Menarini–BlueBee: bioinformatics, –201909 collab developm of MSBiosuite using BlueBee genomics data platoform 2019-09-19
Themis Bioscience–Farallon Capital: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Farallon Capital 2019-09-18
Themis Bioscience–SEVERAL: investment, 201909 financing round Series D €40m co-led by Farallon Capital + Hadean Ventures 2019-09-18
Bayer–Informed Data Systems: digital health, 201909– collab + licensing agreem $10m developm + commercialisaing of One Drop technology platform 2019-09-17
Informed Data Systems–Bayer: investment, 201909 Series B financing incl $20m from Bayer 2019-09-17
Jounce Therapeutics–Yates Network: public relations, 201909 service existent by The Yates Network 2019-09-17
Alder Biopharmaceuticals–Lundbeck: investment, 201909 acquisition tender offer in cash + CVRs up to $1.95b net of cash ANNOUNCED 2019-09-16
Autolus–PPF Group: investment, 201909 acquisition 19.2% stake in market through Nasdaq by PPF Group NV 2019-09-16
Healthy.io–SEVERAL: investment, 201909 financing round Series C $60m led by Corner Ventures 2019-09-12
Inotrem–Invus Group: investment, 201909 financing round Series B totalling €39m incl co-investor Invus 2019-09-12
Inotrem–Morningside: investment, 201909 financing round Series B totalling €39m incl lead investor Morningside Ventures 2019-09-12
Inotrem–SEVERAL: investment, 201909 financing round Series B €39m led by Morningside Ventures 2019-09-12
SpringWorks Therapeutics–SEVERAL: investment, 201909 IPO $162m+$24.3m with 9m+1.35m shares common stock at $18/share at Nasdaq Global Select Market 2019-09-12
Atomwise–JPA Health Communications: public relations, 201909 service existent by JPA 2019-09-11
Avalon Ventures–GSK: investment, 201909 acquisition of Sitari Pharmaceuticals incubated 11/13 as part of GSK/Avalon collaboration 2019-09-11
Capella Therapeutics–Qianzhin Investment Management: investment, 201909 existing investor QZ 2019-09-11
Cedilla Therpapeutics–o2h: drug discovery services, 201909– collab expansion synthetic chemistry services for small molecules for protein regulation 2019-09-11
Denovo Biopharma–Qianzhin Investment Management: investment, 201909 existing investor QZ 2019-09-11
Hansoh Pharmaceutical–Atomwise: AI-based drug discovery, 201909– collab design + discover small-molecule drugs against 11 target proteins 2019-09-11
Agilent–Mobilion: mass spectrometry, 201909– collab integration of SLIM ion mobility technology with Agilent Q-TOF MS platform 2019-09-10
Atropos Therapeutics–Atomwise: AI-based drug discovery, 201909– collab launch joint venture r+d cancer drugs using senescence assay 2019-09-10
Grünenthal–Mesoblast: cell therapy, 201909– strategic collab $15m upfront developm + commercialisation of MPC-06-ID in Europe + Lation America 2019-09-10
Insilico Medicine–Baidu Ventures: investment, 201909 financing round Series B totalling $37m incl co-investor Baidu Ventures 2019-09-10
Insilico Medicine–BOLD Capital Partners: investment, 201909 financing round Series B totalling $37m incl co-investor BOLD Capital Partners 2019-09-10
Insilico Medicine–F-Prime: investment, 201909 financing round Series B totalling $37m incl co-investor F-Prime Capital 2019-09-10
Insilico Medicine–Fidelity: investment, 201909 financing round Series B totalling $37m incl co-investor Eight Roads 2019-09-10
Insilico Medicine–Lilly: investment, 201909 financing round Series B totalling $37m incl co-investor Lilly Asia Ventures 2019-09-10
Insilico Medicine–Pavilion Capital: investment, 201909 financing round Series B totalling $37m incl co-investor Pavilion Capital 2019-09-10
Insilico Medicine–Qiming: investment, 201909 financing round Series B totalling $37m incl lead investor Qiming Venture Partners 2019-09-10
Insilico Medicine–SEVERAL: investment, 201909 financing round Series B $37m led by Qiming Venture Partners 2019-09-10
Insilico Medicine–Sinovation Ventures: investment, 201909 financing round Series B totalling $37m incl co-investor Sinovation Ventures 2019-09-10
Mobilion–CG Life: public relations, 201909 service existent by CG Life 2019-09-10
Mobilion–United States (govt): mass spectrometry, 201909 license existent to LIMS technology from PNNL excl for life science applications 2019-09-10
OncoStatyx–Atomwise: AI-based drug discovery, 201909– collab launch joint venture to discover + develop small molecule KDM5B inhititors for cancer 2019-09-10
Pharvaris–Bain Capital: investment, 201909 financing round Series B totalling $66m incl new + co-investor Bain Capital Life Sciences 2019-09-10
Pharvaris–Foresite Capital: investment, 201909 financing round Series B totalling $66m incl new + lead investor Foresite Capital 2019-09-10
Pharvaris–Idinvest Partners: investment, 201909 financing round Series B totalling $66m incl existing + co-investor Idinvest Partners 2019-09-10
Pharvaris–Kurma: investment, 201909 financing round Series B totalling $66m incl existing + co-investor Kurma Partners 2019-09-10
Pharvaris–Life Sciences Partners: investment, 201909 financing round Series B totalling $66m incl existing + co-investor LSP 2019-09-10
Pharvaris–Rockefeller: investment, 201909 financing round Series B totalling $66m incl new + co-investor Venrock Partners 2019-09-10
Pharvaris–SEVERAL: investment, 201909 financing round Series B $66m led by Foresite Capital 2019-09-10
Pharvaris–VenBio: investment, 201909 financing round Series B totalling $66m incl new + co-investor venBio Partners 2019-09-10
SEngine Precision Medicine–Atomwise: AI-based drug discovery, 201909– collab launch joint venture r+d personalised cancer drugs using gene targets 2019-09-10
4BIO Ventures–SEVERAL: investment, 201909 first closing $50m of 4BIO Ventures II fund targeting $150m 2019-09-09
BioNTech–SEVERAL: investment, 201909–201910 US IPO $150m+$22.5m with 10m+1.5mADSs at $15/ADS at Nasdaq Global Select Market 2019-09-09
Cerevel–W2O Group: public relations, 201909 service existent by W2Opure 2019-09-09
Genmab–Tempus: AI-based drug discovery, 201909– strateg collab multi-year r+d targets + biomarker for personalised cancer drugs 2019-09-09
ADC Therapeutics–SEVERAL: investment, 201909–201910 IPO up to approx $230m at NYSE WITHDRAWN 10/19 2019-09-06
Agilent–SEVERAL: credit, 201909–202909 public offering $500m net $492.8m Senior Notes 2.75% due Sept 2029 2019-09-05
Invitae–SEVERAL: credit, 201909–20224 senior convertible notes $300m net $291.2m due 2024 at 2% 2019-09-05
Roche–Abionic: in vitro diagnostics, 201909– collab developm + supply abioSCOPE IVD PoC asthma test panel for asthma management in US for Genentech 2019-09-05
Sigrid Therapeutics–Joyance Partners: investment, 201909 financing round totalling $1.6m incl co-lead investor Joyance Partners 2019-09-05
1 2 3 ... 64 65 66  next pagenext page



Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 iito 650x80px

» top